Patent ID: 11873533
Assignee: LUCENCE LIFE SCIENCES PTE. LTD.
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 14:
15. The method of claim 14, wherein the gene known to undergo fusion is selected from the group consisting of ALK receptor tyrosine kinase, RET proto-oncogene, ROS proto-oncogene 1, fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2), fibroblast growth factor receptor 3 (FGFR3), neurotrophic receptor tyrosine kinase 1 (NTRK1), neurotrophic receptor tyrosine kinase 2 (NTRK2), neurotrophic receptor tyrosine kinase 3 (NTRK3), neuregulin 1 (NRG1), B-Raf proto-oncogene, serine/threonine kinase (BRAF), transmembrane serine protease 2 (TMPRSS2), MET proto-oncogene, receptor tyrosine kinase (MET), epidermal growth factor receptor (EGFR), estrogen receptor 1 (ESR1), platelet derived growth factor receptor alpha (PDGFRA), androgen receptor (AR), BCR activator of RhoGEF and GTPase (BCR), core-binding factor subunit beta (CBFB), lysine methyltransferase 2A (KMT2A), nucleophosmin 1 (NPM1), PML nuclear body scaffold (PML), and RUNX family transcription factor 1 (RUNX1).